REDUCING BLEEDING AT LOWER SEGMENT CESAREAN SECTION
Conditions
Interventions
CONTROL GROUP
Sponsors
ODUOLAOWOO BAMUS BABTUNDE
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Age = 18 years Patients admitted for primary or secondary caesarean section (Elective or Emergency) Gestational age of 36 to 42 weeks of gestation Singleton pregnancy Informed consent form signed
Exclusion criteria
Exclusion criteria: History of venous (deep vein thrombosis and/or pulmonary embolism) or arterial thrombosis (angina pectoris, myocardial infarction, stroke) Any known cardiovascular, renal, or liver disorders Autoimmune disease Sickle cell disease Severe hemorrhagic disease Planned general anesthesia Placenta previa Abruptio placentae Eclampsia, HELLP syndrome Multiple pregnancy In utero fetal death Administration of low-molecular-weight heparin or antiplatelet agents during the week before delivery Consent not obtained
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the effect of TXA (1g) on post-operative blood loss.;To compare the percentage fall in post-operative haemoglobin between drug and placebo group.;To assess the need for additional uterotonic agents. ;To assess for presence of adverse effect of intravenous TXA ;There was a statistically significant difference in the calculated estimated blood loss among the intervention and the placebo arm of the study (P-value < 0.0001) | — |
Secondary
| Measure | Time frame |
|---|---|
| The prevalence of PPH among the placebo group was four times that of the Tranexamic acid group. (P-value < 0.0001); There was no statistically significant difference in the use of additional uterotonic, blood transfusion and adverse effect profile between the two groups. | — |
Countries
Nigeria
Contacts
Public ContactMAYOWA ADEFUYE
RESEARCH ASSISTANT
Outcome results
None listed